Phathom Pharmaceuticals, Inc. — Director's Dealing 2022

Jan 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2022-01-19

Reporting Person: Nabulsi Azmi (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-19	Common Stock	A	19500	$0.00	Acquired	21378	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-19	Stock Option (Right to Buy)	$15.21	A	97500	Acquired	2032-01-18	Common Stock (97500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	843.42	Indirect
Common Stock	765700	Indirect

Footnotes

F1: Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2: Includes 1,425 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022 and 453 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan which were inadvertenly omitted from the most recent Form 4.

F3: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.